Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-second-quarter-2025-financial-results-and ...
Lineage Cell Therapeutics, Inc. ((LCTX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Brainstorm Cell Therapeutics ( (BCLI)) has released its Q3 earnings. Here is a breakdown of the information Brainstorm Cell Therapeutics presented to its investors. BrainStorm Cell Therapeutics Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback